Rebecca Ivy Hartman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 45 | 2024 | 5798 | 6.990 |
Why?
|
Melanoma | 27 | 2024 | 5689 | 4.310 |
Why?
|
Sunscreening Agents | 6 | 2023 | 139 | 2.070 |
Why?
|
Sunburn | 3 | 2023 | 156 | 1.720 |
Why?
|
Veterans | 5 | 2024 | 2629 | 1.560 |
Why?
|
Sunbathing | 2 | 2023 | 65 | 0.980 |
Why?
|
Protective Clothing | 3 | 2023 | 103 | 0.980 |
Why?
|
Lymphangitis | 1 | 2023 | 15 | 0.880 |
Why?
|
Dermatology | 5 | 2021 | 915 | 0.860 |
Why?
|
Mycobacterium marinum | 1 | 2023 | 29 | 0.860 |
Why?
|
Niacinamide | 2 | 2023 | 413 | 0.820 |
Why?
|
Chemoprevention | 2 | 2023 | 326 | 0.810 |
Why?
|
Prurigo | 1 | 2022 | 25 | 0.800 |
Why?
|
Self-Examination | 1 | 2022 | 71 | 0.790 |
Why?
|
Mohs Surgery | 2 | 2021 | 221 | 0.780 |
Why?
|
Dermatofibrosarcoma | 1 | 2021 | 48 | 0.750 |
Why?
|
Benzene | 1 | 2021 | 106 | 0.740 |
Why?
|
Hair Color | 1 | 2020 | 131 | 0.690 |
Why?
|
Skin Diseases | 6 | 2021 | 1088 | 0.650 |
Why?
|
Directive Counseling | 1 | 2020 | 170 | 0.650 |
Why?
|
Carcinoma, Basal Cell | 1 | 2023 | 558 | 0.590 |
Why?
|
Keratinocytes | 1 | 2021 | 790 | 0.560 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 694 | 0.540 |
Why?
|
Fear | 1 | 2024 | 1463 | 0.510 |
Why?
|
United States | 23 | 2024 | 71902 | 0.480 |
Why?
|
Disabled Persons | 2 | 2023 | 1224 | 0.470 |
Why?
|
Dermoscopy | 3 | 2024 | 66 | 0.460 |
Why?
|
Secondary Prevention | 1 | 2020 | 1474 | 0.440 |
Why?
|
Lip Diseases | 1 | 2013 | 18 | 0.440 |
Why?
|
Stenotrophomonas maltophilia | 1 | 2013 | 18 | 0.430 |
Why?
|
Dyskeratosis Congenita | 1 | 2014 | 73 | 0.430 |
Why?
|
Granuloma Annulare | 1 | 2013 | 29 | 0.430 |
Why?
|
Humans | 69 | 2024 | 757566 | 0.430 |
Why?
|
Early Detection of Cancer | 4 | 2021 | 3164 | 0.410 |
Why?
|
Primary Prevention | 1 | 2020 | 1185 | 0.400 |
Why?
|
Parotid Neoplasms | 1 | 2013 | 157 | 0.390 |
Why?
|
Sunlight | 2 | 2024 | 336 | 0.380 |
Why?
|
Dermatitis | 1 | 2013 | 200 | 0.380 |
Why?
|
Lip | 1 | 2013 | 197 | 0.380 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9245 | 0.380 |
Why?
|
Forecasting | 2 | 2017 | 2919 | 0.370 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2013 | 236 | 0.370 |
Why?
|
Biomedical Research | 2 | 2016 | 3415 | 0.350 |
Why?
|
Skin | 5 | 2023 | 4464 | 0.350 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 25924 | 0.340 |
Why?
|
Career Choice | 1 | 2016 | 752 | 0.330 |
Why?
|
Ultraviolet Rays | 3 | 2023 | 1077 | 0.330 |
Why?
|
Psoriasis | 1 | 2017 | 937 | 0.320 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3809 | 0.320 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2014 | 491 | 0.300 |
Why?
|
Immunocompromised Host | 1 | 2013 | 854 | 0.290 |
Why?
|
Biopsy | 7 | 2021 | 6757 | 0.260 |
Why?
|
Mental Health | 1 | 2020 | 3228 | 0.260 |
Why?
|
Physical Examination | 2 | 2022 | 1245 | 0.250 |
Why?
|
Radiation Dosage | 1 | 2014 | 1957 | 0.250 |
Why?
|
Rectal Neoplasms | 1 | 2012 | 1154 | 0.220 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3970 | 0.220 |
Why?
|
Adult | 19 | 2024 | 219725 | 0.220 |
Why?
|
Adhesives | 1 | 2023 | 65 | 0.210 |
Why?
|
Private Practice | 1 | 2023 | 152 | 0.210 |
Why?
|
Middle Aged | 17 | 2024 | 219192 | 0.200 |
Why?
|
Decision Support Techniques | 1 | 2012 | 1991 | 0.200 |
Why?
|
Habits | 1 | 2023 | 146 | 0.200 |
Why?
|
Pregnancy Complications | 1 | 2016 | 2940 | 0.200 |
Why?
|
Health Surveys | 2 | 2023 | 4056 | 0.190 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2023 | 735 | 0.190 |
Why?
|
Nevus, Halo | 1 | 2020 | 5 | 0.180 |
Why?
|
Lymph Nodes | 1 | 2012 | 3470 | 0.180 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 640 | 0.180 |
Why?
|
Female | 24 | 2024 | 389943 | 0.180 |
Why?
|
Mental Disorders | 1 | 2020 | 6802 | 0.180 |
Why?
|
Receptor, Melanocortin, Type 1 | 1 | 2020 | 74 | 0.180 |
Why?
|
Current Procedural Terminology | 1 | 2021 | 89 | 0.180 |
Why?
|
Aged | 12 | 2024 | 167890 | 0.180 |
Why?
|
Male | 25 | 2024 | 358180 | 0.170 |
Why?
|
Gender Identity | 3 | 2020 | 757 | 0.170 |
Why?
|
Research Design | 1 | 2016 | 6152 | 0.170 |
Why?
|
Honey | 1 | 2019 | 12 | 0.170 |
Why?
|
Folliculitis | 1 | 2019 | 25 | 0.170 |
Why?
|
Registries | 3 | 2022 | 8164 | 0.170 |
Why?
|
Scalp Dermatoses | 1 | 2019 | 44 | 0.160 |
Why?
|
Health Behavior | 2 | 2023 | 2613 | 0.160 |
Why?
|
Staphylococcal Skin Infections | 1 | 2019 | 78 | 0.160 |
Why?
|
Vitamin B Complex | 1 | 2021 | 298 | 0.160 |
Why?
|
Mycosis Fungoides | 1 | 2020 | 170 | 0.160 |
Why?
|
Pandemics | 3 | 2023 | 8600 | 0.160 |
Why?
|
Skin Pigmentation | 1 | 2020 | 276 | 0.150 |
Why?
|
Heterosexuality | 1 | 2020 | 301 | 0.150 |
Why?
|
Retrospective Studies | 8 | 2024 | 79984 | 0.150 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3317 | 0.150 |
Why?
|
Exanthema | 1 | 2022 | 505 | 0.140 |
Why?
|
SEER Program | 1 | 2022 | 1454 | 0.140 |
Why?
|
Demography | 1 | 2022 | 1645 | 0.140 |
Why?
|
Risk Factors | 8 | 2022 | 73708 | 0.140 |
Why?
|
Incidence | 3 | 2023 | 21217 | 0.140 |
Why?
|
Matrix Metalloproteinase 14 | 2 | 2006 | 60 | 0.130 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 907 | 0.130 |
Why?
|
Research Subjects | 1 | 2018 | 249 | 0.130 |
Why?
|
Carcinoma in Situ | 1 | 2022 | 793 | 0.130 |
Why?
|
Prognosis | 5 | 2023 | 29488 | 0.130 |
Why?
|
Neoplasm Staging | 4 | 2023 | 11082 | 0.130 |
Why?
|
Hemangioma | 1 | 2020 | 727 | 0.120 |
Why?
|
Lower Extremity | 1 | 2023 | 1188 | 0.120 |
Why?
|
Alopecia | 1 | 2019 | 411 | 0.120 |
Why?
|
Tumor Burden | 1 | 2021 | 1886 | 0.120 |
Why?
|
Prediabetic State | 1 | 2020 | 547 | 0.120 |
Why?
|
Mass Screening | 2 | 2020 | 5412 | 0.120 |
Why?
|
Nutrition Surveys | 1 | 2021 | 1716 | 0.110 |
Why?
|
Matrix Metalloproteinase 2 | 2 | 2006 | 461 | 0.110 |
Why?
|
Physician Assistants | 1 | 2016 | 188 | 0.110 |
Why?
|
Health Care Surveys | 1 | 2021 | 2425 | 0.110 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 2052 | 0.110 |
Why?
|
Electronic Mail | 1 | 2015 | 213 | 0.110 |
Why?
|
Sexual Behavior | 2 | 2020 | 2154 | 0.110 |
Why?
|
Referral and Consultation | 2 | 2016 | 3579 | 0.110 |
Why?
|
Nurse Practitioners | 1 | 2016 | 268 | 0.110 |
Why?
|
Prevalence | 5 | 2020 | 15640 | 0.100 |
Why?
|
Metformin | 1 | 2020 | 905 | 0.100 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3591 | 0.100 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1051 | 0.100 |
Why?
|
Medical Staff, Hospital | 1 | 2016 | 600 | 0.100 |
Why?
|
Xenopus laevis | 2 | 2006 | 963 | 0.100 |
Why?
|
Interviews as Topic | 2 | 2020 | 2673 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1787 | 0.100 |
Why?
|
Research Personnel | 1 | 2016 | 583 | 0.090 |
Why?
|
Acne Vulgaris | 1 | 2016 | 356 | 0.090 |
Why?
|
Survival Analysis | 1 | 2023 | 10075 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12951 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2022 | 1821 | 0.090 |
Why?
|
Cohort Studies | 3 | 2022 | 41190 | 0.090 |
Why?
|
Mentors | 1 | 2016 | 660 | 0.090 |
Why?
|
Disclosure | 1 | 2015 | 743 | 0.080 |
Why?
|
Health Services Accessibility | 3 | 2022 | 5382 | 0.080 |
Why?
|
Clinical Competence | 3 | 2021 | 4760 | 0.080 |
Why?
|
Behavioral Risk Factor Surveillance System | 2 | 2020 | 204 | 0.080 |
Why?
|
Databases, Factual | 1 | 2024 | 7927 | 0.080 |
Why?
|
Internship and Residency | 2 | 2021 | 5854 | 0.080 |
Why?
|
Gene Expression Profiling | 2 | 2023 | 9403 | 0.080 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4886 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2495 | 0.080 |
Why?
|
Patient Preference | 1 | 2015 | 917 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5638 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7399 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8512 | 0.070 |
Why?
|
Age Factors | 1 | 2023 | 18326 | 0.070 |
Why?
|
Prospective Studies | 4 | 2022 | 54092 | 0.070 |
Why?
|
Metamorphosis, Biological | 1 | 2006 | 37 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2687 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2013 | 20992 | 0.060 |
Why?
|
Artificial Intelligence | 1 | 2020 | 2548 | 0.060 |
Why?
|
Prostatic Neoplasms | 2 | 2022 | 11057 | 0.060 |
Why?
|
Curriculum | 1 | 2019 | 3715 | 0.060 |
Why?
|
Risk Assessment | 3 | 2023 | 23816 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 1 | 2012 | 36270 | 0.060 |
Why?
|
Prostatectomy | 1 | 2013 | 1821 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 1668 | 0.060 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2914 | 0.060 |
Why?
|
Primary Health Care | 2 | 2023 | 4652 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3560 | 0.060 |
Why?
|
Telemedicine | 1 | 2021 | 3013 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7366 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5325 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11709 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2022 | 39020 | 0.050 |
Why?
|
Acantholysis | 1 | 2022 | 11 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2022 | 58558 | 0.050 |
Why?
|
Ichthyosis | 1 | 2022 | 59 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 39811 | 0.050 |
Why?
|
Elastic Tissue | 1 | 2020 | 65 | 0.040 |
Why?
|
Hypopigmentation | 1 | 2020 | 43 | 0.040 |
Why?
|
Telangiectasis | 1 | 2020 | 77 | 0.040 |
Why?
|
Skin Abnormalities | 1 | 2020 | 59 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2012 | 14637 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2019 | 64242 | 0.040 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2020 | 168 | 0.040 |
Why?
|
Cephalexin | 1 | 2019 | 38 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2013 | 11063 | 0.040 |
Why?
|
Hyperpigmentation | 1 | 2020 | 117 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2022 | 603 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2019 | 277 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 634 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3223 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2015 | 4760 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 828 | 0.040 |
Why?
|
Physicians | 1 | 2015 | 4577 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15207 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12078 | 0.030 |
Why?
|
Atrophy | 1 | 2020 | 1627 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2010 | 3152 | 0.030 |
Why?
|
Physician-Patient Relations | 2 | 2020 | 3238 | 0.030 |
Why?
|
Attitude to Computers | 1 | 2015 | 195 | 0.030 |
Why?
|
Pregnancy | 1 | 2016 | 29712 | 0.030 |
Why?
|
Observer Variation | 1 | 2020 | 2599 | 0.030 |
Why?
|
Health Records, Personal | 1 | 2015 | 127 | 0.030 |
Why?
|
Video Recording | 1 | 2019 | 955 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2010 | 4220 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3296 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2847 | 0.030 |
Why?
|
Treatment Failure | 1 | 2019 | 2637 | 0.030 |
Why?
|
Adolescent | 3 | 2020 | 87819 | 0.030 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 411 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2016 | 441 | 0.030 |
Why?
|
Dermatologic Agents | 1 | 2016 | 308 | 0.020 |
Why?
|
Plant Proteins | 1 | 1994 | 368 | 0.020 |
Why?
|
Cost Savings | 1 | 2016 | 913 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3097 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2278 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2144 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2658 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3354 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 2973 | 0.020 |
Why?
|
Age Distribution | 1 | 2015 | 2877 | 0.020 |
Why?
|
Genetic Testing | 1 | 2022 | 3529 | 0.020 |
Why?
|
Oligopeptides | 1 | 1994 | 1184 | 0.020 |
Why?
|
Vitamin D | 1 | 2022 | 3282 | 0.020 |
Why?
|
Self Report | 1 | 2020 | 3709 | 0.020 |
Why?
|
Young Adult | 3 | 2020 | 58755 | 0.020 |
Why?
|
Educational Status | 1 | 2015 | 2511 | 0.020 |
Why?
|
Markov Chains | 1 | 2010 | 965 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2354 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3165 | 0.020 |
Why?
|
Incidental Findings | 1 | 2010 | 693 | 0.020 |
Why?
|
Base Sequence | 2 | 2006 | 12437 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2006 | 3602 | 0.020 |
Why?
|
Population Surveillance | 1 | 2015 | 2599 | 0.010 |
Why?
|
Triiodothyronine | 1 | 2006 | 493 | 0.010 |
Why?
|
Catalytic Domain | 1 | 2006 | 705 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1722 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10135 | 0.010 |
Why?
|
Life Expectancy | 1 | 2010 | 1238 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2006 | 1693 | 0.010 |
Why?
|
Health Care Costs | 1 | 2016 | 3234 | 0.010 |
Why?
|
Internet | 1 | 2015 | 3081 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2015 | 3440 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20037 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6230 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2006 | 2263 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2006 | 1170 | 0.010 |
Why?
|
Animals, Genetically Modified | 1 | 2006 | 1554 | 0.010 |
Why?
|
Point Mutation | 1 | 2006 | 1594 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3864 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2006 | 3593 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13221 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2006 | 4170 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 3793 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2006 | 13442 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2006 | 1722 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2006 | 17615 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 5483 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2006 | 6525 | 0.010 |
Why?
|
Decision Making | 1 | 2010 | 3909 | 0.010 |
Why?
|
Algorithms | 1 | 2016 | 13952 | 0.010 |
Why?
|
DNA | 1 | 2006 | 7200 | 0.010 |
Why?
|
Animals | 2 | 2006 | 167718 | 0.000 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1994 | 3757 | 0.000 |
Why?
|